GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Accumulated other comprehensive income (loss)

Faron Pharmaceuticals Oy (LSE:FARN) Accumulated other comprehensive income (loss) : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Faron Pharmaceuticals Oy's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was £0.00 Mil.

Faron Pharmaceuticals Oy Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Accumulated other comprehensive income (loss) Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Faron Pharmaceuticals Oy Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Faron Pharmaceuticals Oy Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
LSE:BVXP LSE:OXB LSE:ARIX LSE:HVO LSE:SCLP LSE:FUM LSE:REDX LSE:OBD LSE:4BB LSE:ETX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FARON:Finland 4FR:Germany
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Website
https://www.faron.com
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines